EligibleTrials

Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

Recruiting · NCT06860958 · Interventional (participants receive a specific treatment) · Lead sponsor: Tanta University

View the official record on ClinicalTrials.gov →
Depression

Interventions studied

FluoxetinePlaceboRoflumilast

What this trial is about

Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients

Who can take part

Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.